The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin

Anjaiah Srirangam, Monica Milani, Ranjana Mitra, Zhijun Guo, Mariangellys Rodriguez, Hitesh Kathuria, Seiji Fukuda, Anthony Rizzardi, Stephen Schmechel, David G. Skalnik, Louis M. Pelus, David A. Potter

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: Ritonavir is a potential therapeutic agent in lung cancer, but its targets in lung adenocarcinoma are unknown, as are candidate biomarkers for its activity. Methods: RNAi was used to identify genes whose expression affects ritonavir sensitivity. Synergy between ritonavir, gemcitabine, and cisplatin was tested by isobologram analysis. Results: Ritonavir inhibits growth of K-ras mutant lung adenocarcinoma lines A549, H522, H23, and K-ras wild-type line H838. Ritonavir causes G0/G1 arrest and apoptosis. Associated with G0/G1 arrest, ritonavir down-regulates cyclin-dependent kinases, cyclin D1, and retinoblastoma protein phosphorylation. Associated with induction of apoptosis, ritonavir reduces survivin messenger RNA and protein levels more than twofold. Ritonavir inhibits phosphorylation of c-Src and signal transducer and activator of transcription protein 3, which are important events for survivin gene expression and cell growth, and induces cleavage of PARP1. Although knock down of survivin, c-Src, or signal transducer and activator of transcription protein 3 inhibits cell growth, only survivin knock down enhances ritonavir inhibition of growth and survivin overexpression promotes ritonavir resistance. Ritonavir was tested in combination with gemcitabine or cisplatin, exhibiting synergistic and additive effects, respectively. The combination of ritonavir/gemcitabine/ cisplatin is synergistic in the A549 line and additive in the H522 line, at clinically feasible ritonavir concentrations (<10 μM). Conclusions: Ritonavir is of interest for lung adenocarcinoma therapeutics, and survivin is an important target and potential biomarker for its sensitivity. Ritonavir cooperation with gemcitabine/cisplatin might be explained by involvement of PARP1 in repair of cisplatin-mediated DNA damage and survivin in repair of gemcitabine-mediated double-stranded DNA breaks.

Original languageEnglish (US)
Pages (from-to)661-670
Number of pages10
JournalJournal of Thoracic Oncology
Volume6
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Ritonavir
Protease Inhibitors
Lung Neoplasms
HIV
gemcitabine
Cisplatin
STAT Transcription Factors
STAT3 Transcription Factor
Growth
Biomarkers
Phosphorylation
Apoptosis
Gene Expression
Retinoblastoma Protein
Double-Stranded DNA Breaks
Cyclin-Dependent Kinases
Cyclin D1
RNA Interference

Keywords

  • Chemotherapy
  • Non-small cell lung cancer
  • Ritonavir
  • Survivin

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. / Srirangam, Anjaiah; Milani, Monica; Mitra, Ranjana; Guo, Zhijun; Rodriguez, Mariangellys; Kathuria, Hitesh; Fukuda, Seiji; Rizzardi, Anthony; Schmechel, Stephen; Skalnik, David G.; Pelus, Louis M.; Potter, David A.

In: Journal of Thoracic Oncology, Vol. 6, No. 4, 04.2011, p. 661-670.

Research output: Contribution to journalArticle

Srirangam, A, Milani, M, Mitra, R, Guo, Z, Rodriguez, M, Kathuria, H, Fukuda, S, Rizzardi, A, Schmechel, S, Skalnik, DG, Pelus, LM & Potter, DA 2011, 'The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin', Journal of Thoracic Oncology, vol. 6, no. 4, pp. 661-670. https://doi.org/10.1097/JTO.0b013e31820c9e3c
Srirangam, Anjaiah ; Milani, Monica ; Mitra, Ranjana ; Guo, Zhijun ; Rodriguez, Mariangellys ; Kathuria, Hitesh ; Fukuda, Seiji ; Rizzardi, Anthony ; Schmechel, Stephen ; Skalnik, David G. ; Pelus, Louis M. ; Potter, David A. / The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. In: Journal of Thoracic Oncology. 2011 ; Vol. 6, No. 4. pp. 661-670.
@article{4f9dcc45c67a48778587b460fe8e4928,
title = "The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin",
abstract = "Introduction: Ritonavir is a potential therapeutic agent in lung cancer, but its targets in lung adenocarcinoma are unknown, as are candidate biomarkers for its activity. Methods: RNAi was used to identify genes whose expression affects ritonavir sensitivity. Synergy between ritonavir, gemcitabine, and cisplatin was tested by isobologram analysis. Results: Ritonavir inhibits growth of K-ras mutant lung adenocarcinoma lines A549, H522, H23, and K-ras wild-type line H838. Ritonavir causes G0/G1 arrest and apoptosis. Associated with G0/G1 arrest, ritonavir down-regulates cyclin-dependent kinases, cyclin D1, and retinoblastoma protein phosphorylation. Associated with induction of apoptosis, ritonavir reduces survivin messenger RNA and protein levels more than twofold. Ritonavir inhibits phosphorylation of c-Src and signal transducer and activator of transcription protein 3, which are important events for survivin gene expression and cell growth, and induces cleavage of PARP1. Although knock down of survivin, c-Src, or signal transducer and activator of transcription protein 3 inhibits cell growth, only survivin knock down enhances ritonavir inhibition of growth and survivin overexpression promotes ritonavir resistance. Ritonavir was tested in combination with gemcitabine or cisplatin, exhibiting synergistic and additive effects, respectively. The combination of ritonavir/gemcitabine/ cisplatin is synergistic in the A549 line and additive in the H522 line, at clinically feasible ritonavir concentrations (<10 μM). Conclusions: Ritonavir is of interest for lung adenocarcinoma therapeutics, and survivin is an important target and potential biomarker for its sensitivity. Ritonavir cooperation with gemcitabine/cisplatin might be explained by involvement of PARP1 in repair of cisplatin-mediated DNA damage and survivin in repair of gemcitabine-mediated double-stranded DNA breaks.",
keywords = "Chemotherapy, Non-small cell lung cancer, Ritonavir, Survivin",
author = "Anjaiah Srirangam and Monica Milani and Ranjana Mitra and Zhijun Guo and Mariangellys Rodriguez and Hitesh Kathuria and Seiji Fukuda and Anthony Rizzardi and Stephen Schmechel and Skalnik, {David G.} and Pelus, {Louis M.} and Potter, {David A.}",
year = "2011",
month = "4",
doi = "10.1097/JTO.0b013e31820c9e3c",
language = "English (US)",
volume = "6",
pages = "661--670",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

TY - JOUR

T1 - The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin

AU - Srirangam, Anjaiah

AU - Milani, Monica

AU - Mitra, Ranjana

AU - Guo, Zhijun

AU - Rodriguez, Mariangellys

AU - Kathuria, Hitesh

AU - Fukuda, Seiji

AU - Rizzardi, Anthony

AU - Schmechel, Stephen

AU - Skalnik, David G.

AU - Pelus, Louis M.

AU - Potter, David A.

PY - 2011/4

Y1 - 2011/4

N2 - Introduction: Ritonavir is a potential therapeutic agent in lung cancer, but its targets in lung adenocarcinoma are unknown, as are candidate biomarkers for its activity. Methods: RNAi was used to identify genes whose expression affects ritonavir sensitivity. Synergy between ritonavir, gemcitabine, and cisplatin was tested by isobologram analysis. Results: Ritonavir inhibits growth of K-ras mutant lung adenocarcinoma lines A549, H522, H23, and K-ras wild-type line H838. Ritonavir causes G0/G1 arrest and apoptosis. Associated with G0/G1 arrest, ritonavir down-regulates cyclin-dependent kinases, cyclin D1, and retinoblastoma protein phosphorylation. Associated with induction of apoptosis, ritonavir reduces survivin messenger RNA and protein levels more than twofold. Ritonavir inhibits phosphorylation of c-Src and signal transducer and activator of transcription protein 3, which are important events for survivin gene expression and cell growth, and induces cleavage of PARP1. Although knock down of survivin, c-Src, or signal transducer and activator of transcription protein 3 inhibits cell growth, only survivin knock down enhances ritonavir inhibition of growth and survivin overexpression promotes ritonavir resistance. Ritonavir was tested in combination with gemcitabine or cisplatin, exhibiting synergistic and additive effects, respectively. The combination of ritonavir/gemcitabine/ cisplatin is synergistic in the A549 line and additive in the H522 line, at clinically feasible ritonavir concentrations (<10 μM). Conclusions: Ritonavir is of interest for lung adenocarcinoma therapeutics, and survivin is an important target and potential biomarker for its sensitivity. Ritonavir cooperation with gemcitabine/cisplatin might be explained by involvement of PARP1 in repair of cisplatin-mediated DNA damage and survivin in repair of gemcitabine-mediated double-stranded DNA breaks.

AB - Introduction: Ritonavir is a potential therapeutic agent in lung cancer, but its targets in lung adenocarcinoma are unknown, as are candidate biomarkers for its activity. Methods: RNAi was used to identify genes whose expression affects ritonavir sensitivity. Synergy between ritonavir, gemcitabine, and cisplatin was tested by isobologram analysis. Results: Ritonavir inhibits growth of K-ras mutant lung adenocarcinoma lines A549, H522, H23, and K-ras wild-type line H838. Ritonavir causes G0/G1 arrest and apoptosis. Associated with G0/G1 arrest, ritonavir down-regulates cyclin-dependent kinases, cyclin D1, and retinoblastoma protein phosphorylation. Associated with induction of apoptosis, ritonavir reduces survivin messenger RNA and protein levels more than twofold. Ritonavir inhibits phosphorylation of c-Src and signal transducer and activator of transcription protein 3, which are important events for survivin gene expression and cell growth, and induces cleavage of PARP1. Although knock down of survivin, c-Src, or signal transducer and activator of transcription protein 3 inhibits cell growth, only survivin knock down enhances ritonavir inhibition of growth and survivin overexpression promotes ritonavir resistance. Ritonavir was tested in combination with gemcitabine or cisplatin, exhibiting synergistic and additive effects, respectively. The combination of ritonavir/gemcitabine/ cisplatin is synergistic in the A549 line and additive in the H522 line, at clinically feasible ritonavir concentrations (<10 μM). Conclusions: Ritonavir is of interest for lung adenocarcinoma therapeutics, and survivin is an important target and potential biomarker for its sensitivity. Ritonavir cooperation with gemcitabine/cisplatin might be explained by involvement of PARP1 in repair of cisplatin-mediated DNA damage and survivin in repair of gemcitabine-mediated double-stranded DNA breaks.

KW - Chemotherapy

KW - Non-small cell lung cancer

KW - Ritonavir

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=79953025303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953025303&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31820c9e3c

DO - 10.1097/JTO.0b013e31820c9e3c

M3 - Article

C2 - 21270666

AN - SCOPUS:79953025303

VL - 6

SP - 661

EP - 670

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -